nach oben

Erschienen in:

01.07.2015 | Original Paper

Economic implications of intra-aortic balloon support for myocardial infarction with cardiogenic shock: an analysis from the IABP-SHOCK II-trial

verfasst von: Andreas Schuster, Maggie Faulkner, Uwe Zeymer, Taoufik Ouarrak, Ingo Eitel, Steffen Desch, Gerd Hasenfuß, Holger Thiele

Erschienen in: Clinical Research in Cardiology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The Intra-aortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial has demonstrated the safety of intra-aortic balloon (IABP) support in patients with acute myocardial infarction (AMI) complicated by cardiogenic shock, but no beneficial effect on mortality. Currently, intra-aortic balloon pumping is still the most widely used support device. However, little is known about the economic implications associated with this device.

Methods

Data of 600 patients included in the IABP-SHOCK II trial (registered at ClinicalTrials.gov, NCT00491036) with follow-up at 30 days, 6 and 12 months were subjected to an economic analysis. Patients with cardiogenic shock complicating AMI were randomly assigned to IABP additionally to optimal medical therapy (OMT; n = 301) or OMT alone (n = 299) before early revascularization. Costs were calculated from the perspective of a German healthcare payer. Cost-effectiveness and cost–utility analyses were performed using quality-adjusted life years (QALY) and reduction in New York Heart Association (NYHA) and Canadian Cardiac Society (CCS) class as effectiveness measures.

Results

There was a statistically significant difference in overall costs between the IABP (33,155 ± 14,593 €) and the control group (32,538 ± 14,031 €, p < 0.00001). This was predominantly attributed to the IABP costs in the IABP (760 ± 174 €) versus control group (64 ± 218 €, p < 0.0001) whilst the intensive care unit costs did not differ between the groups (29,177 ± 12,013 € and 29,401 ± 12,063 €, p = 0.82). There was no significant difference in QALY or NYHA and CCS reduction, respectively (p = n.s.).

Conclusion

IABP support is associated with higher healthcare costs as compared to conservative treatment regimens. Clinically, IABP support cannot generally be recommended in AMI complicated by cardiogenic shock in the absence of a mortality benefit. However, economically considering the relatively little contribution to overall costs generated by IABP therapy it may still be considered if clinical scenarios with an IABP-induced benefit may be identified in the future.

Stretch R, Sauer CM, Yuh DD, Bonde P (2014) National trends in the utilization of short-term mechanical circulatory support: incidence, outcomes, and cost analysis. J Am Coll Cardiol 64(14):1407–1415. doi:10.1016/j.jacc.2014.07.958 PubMedCrossRef

Thiele H, Schuler G (2009) Cardiogenic shock: to pump or not to pump? Eur Heart J 30(4):389–390. doi:10.1093/eurheartj/ehp030 PubMedCrossRef

Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC, Cardiology ACo, Association AH, Society CC (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). vol 44. doi:10.1016/j.jacc.2004.07.002

Van de Werf F, Bax J, Betriu A, Blömstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, CPG ECfPG (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. doi:10.1093/eurheartj/ehn416

Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernández-Avilés F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van t Hof A, Widimsky P, Zahger D (2012) ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. doi:10.1093/eurheartj/ehs215

O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. doi:10.1016/j.jacc.2012.11.018

Sjauw KD, Engström AE, Vis MM, van der Schaaf RJ, Baan J, Koch KT, de Winter RJ, Piek JJ, Tijssen JGP, Henriques JPS (2009) A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J 30(4):459–468. doi:10.1093/eurheartj/ehn602 PubMedCrossRef

Thiele H, Schuler G, Neumann F-J, Hausleiter J, Olbrich H-G, Schwarz B, Hennersdorf M, Empen K, Fuernau G, Desch S, de Waha S, Eitel I, Hambrecht R, Böhm M, Kurowski V, Lauer B, Minden H-H, Figulla H-R, Braun-Dullaeus RC, Strasser RH, Rochor K, Maier SKG, Möllmann H, Schneider S, Ebelt H, Werdan K, Zeymer U (2012) Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J 163(6):938–945. doi:10.1016/j.ahj.2012.03.012 PubMedCrossRef

Thiele H, Zeymer U, Neumann F-J, Ferenc M, Olbrich H-G, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Böhm M, Ebelt H, Schneider S, Schuler G, Werdan K (2012) Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 367(14):1287–1296. doi:10.1056/NEJMoa1208410 PubMedCrossRef

10.

Thiele H, Zeymer U, Neumann F-J, Ferenc M, Olbrich H-G, Hausleiter J, de Waha A, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Lauer B, Böhm M, Ebelt H, Schneider S, Werdan K, Schuler G, IBPicsII-SIt Investigators (2013) Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 382(9905):1638–1645. doi:10.1016/S0140-6736(13)61783-3 PubMedCrossRef

11.

De Silva K, Lumley M, Kailey B, Alastruey J, Guilcher A, Asrress KN, Plein S, Marber M, Redwood S, Perera D (2014) Coronary and microvascular physiology during intra-aortic balloon counterpulsation. JACC Cardiovasc Interv 7(6):631–640. doi:10.1016/j.jcin.2013.11.023 PubMedCrossRef

12.

Maini BS, O’Neill W, Palacios I, Dixon S, Gregory D (2012) Cost-effectiveness and quality of life improvements: Impella hemodynamic support compared with intra-aortic balloon pump in high risk patients receiving PCI. J Am Coll Cardiol 59(13s1):E68. doi:10.1016/S0735-1097(12)60069-2 CrossRef

13.

Roos JB, Doshi SN, Konorza T, Palacios I, Schreiber T, Borisenko OV, Henriques JPS (2013) The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspective. J Med Econ 16(3):381–390. doi:10.3111/13696998.2012.762004 PubMedCrossRef

14.

Dietl CA, Berkheimer MD, Woods EL, Gilbert CL, Pharr WF, Benoit CH (1996) Efficacy and cost-effectiveness of preoperative IABP in patients with ejection fraction of 0.25 or less. Ann Thorac Surg 62(2):401–408 (discussion 408–409)PubMedCrossRef

15.

Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H, Liljas B, Petitti D, Reed S (2005) Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Paper presented at the value in health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research

16.

G-DRG-System GIftHRSI (2014) Fallpauschalen-Katalog 2014. http://www.g-drg.de/cms/inek_site_de/G-DRG-System_2014/Fallpauschalen-Katalog/Fallpauschalen-Katalog_2014. Accessed 14 July 2014

17.

Gregory D, Scotti DJ, de Lissovoy G, Palacios I, Dixon S, Maini B, O’Neill W (2013) A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention. Am Health Drug Benefits 6(2):88–99PubMedCentralPubMed

18.

Dorenkamp M, Boldt J, Leber AW, Sohns C, Roser M, Boldt L-H, Haverkamp W, Bonaventura K (2013) Cost-effectiveness of paclitaxel-coated balloon angioplasty in patients with drug-eluting stent restenosis. Clin Cardiol 36(7):407–413. doi:10.1002/clc.22130 PubMedCrossRef

19.

Schweikert B, Hahmann H, Steinacker JM, Imhof A, Muche R, Koenig W, Liu Y, Leidl R (2009) Intervention study shows outpatient cardiac rehabilitation to be economically at least as attractive as inpatient rehabilitation. Clin Res Cardiol 98(12):787–795. doi:10.1007/s00392-009-0081-6 PubMedCrossRef

20.

Kolominsky-Rabas PL, Heuschmann PU, Marschall D, Emmert M, Baltzer N, Neundörfer B, Schöffski O, Krobot KJ (2006) Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 37(5):1179–1183. doi:10.1161/01.STR.0000217450.21310.90 PubMedCrossRef

21.

EuroQolGroup (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208CrossRef

22.

de Waha S, Desch S, Eitel I, Fuernau G, Lurz P, Sandri M, Schuler G, Thiele H (2014) Intra-aortic balloon counterpulsation—basic principles and clinical evidence. Vascul Pharmacol 60(2):52–56. doi:10.1016/j.vph.2013.12.003 PubMedCrossRef

23.

Hochman JS (2003) Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 107(24):2998–3002. doi:10.1161/01.CIR.0000075927.67673.F2 PubMedCrossRef

24.

Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann F-J, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Members ATF (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35(37):2541–2619. doi:10.1093/eurheartj/ehu278 PubMedCrossRef

25.

Thiele H, Lauer B, Hambrecht R, Boudriot E, Sick P, Niebauer J, Falk V, Schuler G (2003) Short- and long-term hemodynamic effects of intra-aortic balloon support in ventricular septal defect complicating acute myocardial infarction. Am J Cardiol 92(4):450–454. doi:10.1016/S0002-9149(03)00665-9 PubMedCrossRef

Titel: Economic implications of intra-aortic balloon support for myocardial infarction with cardiogenic shock: an analysis from the IABP-SHOCK II-trial
verfasst von: Andreas Schuster
Maggie Faulkner
Uwe Zeymer
Taoufik Ouarrak
Ingo Eitel
Steffen Desch
Gerd Hasenfuß
Holger Thiele
Publikationsdatum: 01.07.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Research in Cardiology / Ausgabe 7/2015
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-015-0819-2

Neu im Fachgebiet Kardiologie

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Weniger Extremitätenischämien mit dualer Plättchenhemmung

02.05.2024 Thrombozytenaggregationshemmer Nachrichten

Eine Behandlung mit Ticagrelor zusätzlich zu ASS kann das Risiko für Revaskularisierungen und Amputationen von Extremitäten bei Diabetikern mit stabiler KHK deutlich reduzieren, vor allem für solche mit PAVK. Dafür spricht eine Auswertung der Interventionsstudie THEMIS.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Economic implications of intra-aortic balloon support for myocardial infarction with cardiogenic shock: an analysis from the IABP-SHOCK II-trial